Drugs / Investigational live attenuated mumps vaccine
Investigational live attenuated mumps vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05065177 | Jan → Mar 2016 | mumps infectious disease | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02692599 | Jan → Mar 2016 | mumps infectious disease | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | investigational live attenuated mumps vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02692599 ↗ |
| Modality | Vaccine | “investigational live attenuated mumps vaccine” NCT02692599 ↗ |
| Route | Intramuscular | “Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0” NCT02692599 ↗ |